Abstract
Primary microcephaly is a congenital neurodevelopmental disorder of reduced head circumference and brain volume, with fewer neurons in the cortex of the developing brain due to premature transition between symmetrical and asymmetrical cellular division of the neuronal stem cell layer during neurogenesis. We now show through linkage analysis and whole exome sequencing, that a dominant mutation in ALFY, encoding an autophagy scaffold protein, causes human primary microcephaly. We demonstrate the dominant effect of the mutation in drosophila: transgenic flies harboring the human mutant allele display small brain volume, recapitulating the disease phenotype. Moreover, eye-specific expression of human mutant ALFY causes rough eye phenotype. In molecular terms, we demonstrate that normally ALFY attenuates the canonical Wnt signaling pathway via autophagy-dependent removal specifically of aggregates of DVL3 and not of Dvl1 or Dvl2. Thus, autophagic attenuation of Wnt signaling through removal of Dvl3 aggregates by ALFY acts in determining human brain size.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing / genetics*
-
Animals
-
Animals, Genetically Modified
-
Autophagy-Related Proteins
-
Brain / growth & development
-
Brain / metabolism
-
Brain / pathology
-
Dishevelled Proteins
-
Drosophila
-
Genetic Linkage
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Membrane Proteins / genetics*
-
Microcephaly / genetics*
-
Microcephaly / pathology
-
Mutation
-
Organ Size / genetics
-
Phosphoproteins / genetics*
-
Transcription Factors / genetics*
-
Wnt Signaling Pathway / genetics
Substances
-
Adaptor Proteins, Signal Transducing
-
Autophagy-Related Proteins
-
DVL1 protein, human
-
DVL2 protein, human
-
DVL3 protein, human
-
Dishevelled Proteins
-
Membrane Proteins
-
Phosphoproteins
-
Transcription Factors
-
WDFY3 protein, human
Grants and funding
Funding for this research was provided by Teva Pharmaceutical Industries Ltd. as part of the Israeli National Network of Excellence in Neuroscience (NNE) established by Teva, and by the Legacy Heritage Bio-Medical Program of the Israel Science Foundation (grant no. 1814/13). RK was financed through a Teva Israeli National Network of Excellence in Neuroscience (NNE) grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.